Trial Profile
A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Lenzilumab (Primary) ; Remdesivir (Primary)
- Indications Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms ACTIV-5; ACTIV-5/BET-B; ACTIV-5BET; BET
- 12 Jul 2022 Primary endpoint (Occurrence of mechanical ventilation or death at any point through Day 29 in subjects with ordinal scores of 5 or 6 at baseline) has not been met, according to a Humanigen media release.
- 12 Jul 2022 Preliminary topline results published in the Humanigen Media Release.
- 30 Jun 2022 According to a Humanigen media release, the company has received a notice from NIH/NIAID that they have cleaned and locked the blinded data in the study. The company expects to receive topline results from NIH/NIAID in July.